In the overall post-MI cohort treated with statins and/or ezetimibe (n = 2977), 293 (9.8%) resulted eligible for PCSK9 inhibitors according to ESC/EAS criteria (Table 3). This evidence concerns the gene PCSK9 and myocardial infarction.